News

  • 1 November 2011

    Pfizer acquires Icagen

    Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.

  • 1 November 2011

    FDA clears Vegenics VGX-100 drug trial

    The US Food and Drug Administration (FDA) has approved an investigational new drug application from Vegenics, a subsidiary of Circadian Technologies, to commence clinical trials of VGX-100 for the treatment...

  • 31 October 2011

    FDA approves Mylan pain drug

    Mylan's abbreviated new drug application for morphine sulphate extended-release tablets has been approved by the US Food and Drug Administration (FDA) .

  • 30 October 2011

    Bionovo commences Menerba drug Phase 3 trial

    Biotech company Bionovo has begun a Phase 3 clinical trial designed to assess the safety and efficacy of two doses of oral estrogen receptor beta (ER-b) selective drug, Menerba (MF101),...

  • 30 October 2011

    KemPharm to develop new pain therapy

    KemPharm is planning to initiate the development of KP511, an oral prodrug of hydromorphone that is used to manage pain in patients where an opioid analgesic is appropriate.

  • 30 October 2011

    Biotie and Merck turn their backs on Newron

    Finland’s Biotie Therapies has pulled out of its planned merger with Newron Pharmaceuticals following a decision by Merck to return the full global rights to investigational Parkinson's disease drug safinamide...

  • 30 October 2011

    Bristol-Myers Squibb reports strong revenue rise

    Bristol-Myers Squibb (BMS) has reported strong third quarter results, announcing an 11% increase in revenue to $5.35bn attributed to the company’s blood thinning drug Plavix.

Close
Close
Close

Go Top